IIQ.AX

Healthcare Diagnostics & Research

INOVIQ Ltd

A$0.17

+0.00 +0.00% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 10:20 AM ET	0.17

Key Stats

Market Cap

23.93M

Avg Volume

149,673

EPS

-A$0.06

52W High

A$0.57

52W Low

A$0.16

Div. Yield

0.0%

Analyst Ratings

Strong Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

17.00

P/B Ratio

1.27

P/S Ratio

10.81

EV/EBITDA

-2.22

EV/Revenue

6.71

Margins

Gross Margin (114.3%)

Operating Margin (343.8%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

11.3%

Return on Equity

(42.2%)

Return on Assets

(25.4%)

Liquidity & Leverage

Current Ratio

9.37

Quick Ratio

9.06

Debt / Equity

0.02

Total Cash

9.35M

Total Debt

289,390

About

INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasive diagnostics using its proprietary exosome development technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.